Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TriMix-DC + ipilimumab
- Development stage
- Unknown
- Lead developer
- Universitair Ziekenhuis Brussel
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intravenous, Intradermal, Intranodal
01
Overview
TriMix-DC + ipilimumab is an investigational combination immunotherapy for the treatment of advanced malignant melanoma. It consists of an autologous dendritic cell-based vaccine (TriMix-DC) and the immune checkpoint inhibitor ipilimumab. The TriMix-DC component involves monocyte-derived dendritic cells electroporated with synthetic mRNA encoding a 'TriMix' of activating molecules (CD70, CD40 ligand, and constitutively active TLR4) and four melanoma-associated antigens (tyrosinase, gp100, MAGE-A3, and MAGE-C2). This vaccine is designed to stimulate a robust T-cell response against tumor cells. Ipilimumab, a monoclonal antibody targeting CTLA-4, is added to enhance this immune response by removing inhibitory signals on T-cells. The combination has been studied in Phase II clinical trials led by researchers at Universitair Ziekenhuis Brussel.
- Other names
- TriMix-DC plus ipilimumabAutologous TriMix-DC therapeutic vaccine in combination with ipilimumab
02
Targets
CD27 (Cluster of Differentiation 27)CD40 (Cluster of differentiation 40 receptor)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on TriMix-DC + ipilimumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TriMix-DC + ipilimumab.